Peter Hofland, PhD's Blog Posts Tagged 'carcinoma' (24)

Experts Urge Pediatricians to Educate Families about Dangers of Artificial Tanning As Rates Of Skin Cancer Rise Among Youth

Health experts are urging government regulators to take action to protect the nation's youth by restricting the use of artificial tanning devices, which are linked to an increase in the risk of skin cancer, according to an article published online in the March 18, 2013 edition of Pediatrics, the journal of the American Academy of Pediatrics.

Indoor tanning has grown rapidly over the years with…

Continue

Added by Peter Hofland, PhD on March 18, 2013 at 8:00am — No Comments

Combination of EGFR and COX-2 Inhibitors may Prevent Head and Neck Cancer in High-risk Patients

A new drug combination including an EGFR and COX-2 Inhibitors shows promise in reducing the risk for patients with advanced oral precancerous lesions to develop squamous cell carcinoma of the head and neck. The results of the study, which included preclinical and clinical analyses, were published in Clinical Cancer Research, a journal of the American Association for Cancer…

Continue

Added by Peter Hofland, PhD on February 19, 2013 at 8:00pm — No Comments

New Phase III Trial Results on Pazopanib and Temsirolimus Have Important Implications for Patients Advanced Renal Cell Carcinoma

New results from phase III trials exploring treatment options for patients with advanced renal cell carcinoma were released at the ESMO 2012 Congress of the European Society for Medical Oncology in Vienna (September 28 - October 2, 2012). Renal cell carcinoma, also called kidney cancer or renal adenocarcinoma, is a type of kidney cancer that starts in the lining of the tubules in the kidney. 

Prof Maria De Santis from Kaiser Franz Josef-Spital, Vienna, Chair of the ESMO 2012…

Continue

Added by Peter Hofland, PhD on October 1, 2012 at 8:00pm — No Comments

First Patient Dosed in Phase Ib/IIa Study of CRLX101 in Combination with Bevacizumab in Renal Cancer

Earlier this week the first patient has been dosed in a Phase Ib/IIa study of CRLX101 (formerly called IT-101, Cerulean Pharma Inc.), dual inhibitor of topoisomerase 1 and hypoxia-inducible factor-1 alpha, in combination with bevacizumab (Avastin®, Genentech/Roche) in metastatic renal cell carcinoma (mRCC) patients. Cerulean also announced the completion of enrollment of its randomized Phase II study in advanced non-small…

Continue

Added by Peter Hofland, PhD on July 2, 2012 at 7:00pm — No Comments

HIV-infected Patients May Benefit fom Earlier Antiretroviral Therapy Designed to Reduce Burden of Cancer

HIV-infected patients are at increased risk for cancer as a result of both their impaired immune system and lifestyle factors, such as smoking, according to researchers at Kaiser Permanente.



The study, which appears in the current issue of Cancer Epidemiology, Biomarkers and Prevention, is among the first to directly compare the…

Continue

Added by Peter Hofland, PhD on November 22, 2011 at 11:00am — No Comments

Use of Analgesics -Acetaminophen and Nonaspirin NSAID- Associated With Increased Risk for Renal Cell Carcinoma

Use of acetaminophen and nonaspirin nonsteroidal anti-inflammatory drugs (NSAID) was associated with a significantly increased risk for developing renal cell carcinoma, according to data presented at the 10th AACR International Conference on Frontiers in Cancer Prevention Research, held in Boston, Massachusetts (USA), Oct. 22-25, 2011.…

Continue

Added by Peter Hofland, PhD on October 24, 2011 at 4:30pm — No Comments

Indoor Tanning Increases Risk for Deadly Skin Cancers

Researchers confirmed an association between tanning bed use and an increased risk for three common skin cancers — basal cell carcinoma, squamous cell carcinoma and melanoma, according to results presented at the 10th AACR International Conference on Frontiers in Cancer Prevention Research, held in Boston, Massachusetts (USA), Oct. 22-25,…

Continue

Added by Peter Hofland, PhD on October 24, 2011 at 4:30pm — No Comments

Study Found Antiparasitic Drugs May Provide Long-Term Protection Against Skin Cancer

An antiparasitic agent used to treat African sleeping sickness (Human African trypanosomiasis or HAT)might someday be used to prevent nonmelanoma skin cancers. Researchers found that Eflornithine (DFMO, or α-difluoromethylornithine), still appeared to protect against nonmelanoma skin cancers years after people stopped taking the drug, according to a poster presented at the 10th AACR International Conference on…

Continue

Added by Peter Hofland, PhD on October 23, 2011 at 4:30pm — No Comments

Possible Link Found Between Bacterium and Colon Cancer

For the first time, scientists at Dana-Farber Cancer Institute and the Broad Institute have found strikingly high levels of a bacterium in colorectal cancers. The researchers believe that the bacterium may contribute to the disease and could potentially be a key to diagnosing, preventing, and treating it.



In a study published online in the…

Continue

Added by Peter Hofland, PhD on October 17, 2011 at 5:00pm — No Comments

Merkel Cell Polyomavirus Responsible for Rare Skin Cancer - Narrowing Possible Treatments

Scientists at the University of Pittsburgh Cancer Institute have begun to uncover how the virus that causes most Merkel cell carcinoma (MCC) – a rare and aggressive skin cancer – operates, meaning that a rational chemotherapeutic target for this cancer could be developed in the near future.



Patrick Moore, M.D., M.P.H., an American Cancer Society…

Continue

Added by Peter Hofland, PhD on September 15, 2011 at 11:00am — No Comments

Vismodegib Helps Shrink Tumors; Healing Lesions in Advanced Basal Cell Carcinoma

A pivotal Phase II study with vismodegib (RG3616/GDC-0449, Roche / Genentech) showed positive results in people with advanced basal cell carcinoma (BCC) for whom surgery is considered inappropriate.



The full results of the study will be presented at the Seventh European Association of Dermato-Oncology… Continue

Added by Peter Hofland, PhD on June 20, 2011 at 10:00am — No Comments

Trabedersen Shows Excellent Safety Profile and Efficacy in Solid Tumors

Trabedersen (AP 12009, Anitisense Pharma GmbH), a novel TGF-β2 inhibitor, has achieves proof of concept for systemic intravenous application as monotherapy. Data from an ongoing clinical Phase I/II trial with intravenous monotherapy of trabedersen for the treatment of patients with advanced… Continue

Added by Peter Hofland, PhD on June 7, 2011 at 2:30am — No Comments

Scientists Discover Novel Drug Target for Squamous Cell Carcinoma

Researchers at the Fred Hutchinson Cancer Research Center have discovered a new drug target for squamous cell carcinoma – the second most common form of skin cancer. Scientists in the laboratory of Valeri Vasioukhin, Ph.D., have found that a protein called alpha-catenin acts as a tumor suppressor and they also have unlocked the mechanism by which this protein controls cell proliferation.



The findings by… Continue

Added by Peter Hofland, PhD on May 19, 2011 at 3:30pm — No Comments

FDA Approves Special Protocol Assessmen for Novel Therapeutic Targeting Cancer Metabolism

The U.S. Food & Drug Administration (FDA) has approved a Special Protocol Assessment (SPA) for a Phase III clinical trial of pegylated arginine deiminase (ADI-PEG 20, Polaris Group) in patients with advanced hepatocellular carcinoma (HCC).



ADI-PEG 20 is a novel protein therapeutic that has demonstrated anti-tumor activity and safety in Phase I & II clinical trials of patients with metastatic…

Continue

Added by Peter Hofland, PhD on March 31, 2011 at 5:00am — No Comments

Molecular 'Switch' Turns Stem Cells On or Off - New Clue May Help Patients with Squamous Cell Carcinoma

An intriguing question for many researchers: How do organs 'know' when to stop growing? The answer could be useful in regenerative medicine, and also in cancer – where these "stop growing" signals either aren't issued or aren't heeded. Researchers in the Stem Cell Program at Children's Hospital Boston have now found a regulator of gene activity that… Continue

Added by Peter Hofland, PhD on March 3, 2011 at 9:00am — No Comments

Dramatic Improvement in the Development of Novel Treatements for Melanoma

Although considerable work is underway in the development of new approaches to therapy for melanoma, an aggressive form of skin cancer that begins in skin cells called melanocytes, primary prevention continues to serve as the leading strategy. While not as common as other major types of skin cancer, including basal cell and squamous cell carcinoma, the average lifetime risk of developing skin melanoma is about 1%.…



Continue

Added by Peter Hofland, PhD on February 4, 2011 at 5:30am — No Comments

Four-year old Canadian Girl Thought to be Youngest Breast Cancer Survivor

Aleisha Hunter, a 4-year old girl from Cambridge, Ontario (Canada), is thought to be the youngest breast cancer survivor in the world.



Today, the broad smile on her face and her abundant energy, so typical for a girl of her age, does not show the 15-month-long medical nightmare she endured that ultimately led medical staff in the North York General Hospital (Ontario, Canada) to a diagnosis of a rare form of breast cancer and a surgery for a radical…

Continue

Added by Peter Hofland, PhD on January 20, 2011 at 7:00am — No Comments

Targeted Gold Nanoparticles and Noninvasive Radio Fields May Offer New Treatment Option for Pancreatic Carcinomas

Research conducted in the Kanzius/Curley Lab at The University of Texas M.D. Anderson Cancer Center for the first time demonstrates that radiofrequency fields can treat pancreatic andenocarcinomas[1]. The researchers found that noninvasive radiofrequency (RF) fields were effective in controlling relatively large pancreatic cancer cells without any…

Continue

Added by Peter Hofland, PhD on January 13, 2011 at 3:00pm — No Comments

Phase I Data Shows Human Proof-of-concept and Confirms Advancement RNAi for the Treatment of Liver Cancer

Analysis of human tissue samples in a Phase I human clinical trial with ALN-VSP (Alnylam Pharmaceuticals), for the first time demonstrated strong proof of RNAi in man. ALN-VSP, an RNAi therapeutic for the treatment of hepatocellular carcinoma and other solid tumors with liver involvement, contains two small interfering RNAs (siRNAs) formulated in a proprietary first generation lipid nanoparticle (LNP) formulation developed by…

Continue

Added by Peter Hofland, PhD on January 13, 2011 at 5:30am — No Comments

Researchers Find Gene Associated With Aggressive Skin Cancer

The loss of a gene known as INPP5A could predict the onset, and track the progression, of an aggressive type of skin cancer, according to a study published today by the Arizona Cancer Center, one of 40 centers in the nation designated by the National Cancer Institute as a Comprehensive Cancer Center, the Mayo Clinic and the Translational Genomics Research Institute (TGen).



Targeting INPP5A could provide physicians with better ways to prevent and treat… Continue

Added by Peter Hofland, PhD on September 28, 2010 at 10:30am — No Comments

Monthly Archives

2013

2012

2011

2010

2009

2008

2007

2005

2004

2001

ADVERTISEMENT

Onco'Zine is present here

© 2013   Created by Peter Hofland, PhD.

Badges  |  Report an Issue  |  Terms of Service

Find us on Google+